Dupilumab therapy of atopic dermatitis of the elderly : a multicentre, real-life study
© 2020 European Academy of Dermatology and Venereology..
BACKGROUND: Treatment of moderate-to-severe atopic dermatitis (AD) in the elderly may be challenging, due to side-effects of traditional anti-inflammatory drugs and to comorbidities often found in this age group. Furthermore, efficacy and safety of innovative drugs such as dupilumab are not yet well known.
OBJECTIVES: A multicentre retrospective, observational, real-life study on the efficacy and safety of dupilumab was conducted in a group of patients aged ≥65 years and affected by severe AD. Their main clinical features were also examined.
METHODS: Data of elderly patients with severe (EASI ≥24) AD treated with dupilumab at label dosage for 16 weeks were retrospectively collected. Treatment outcome was assessed by comparing objective (EASI) and subjective (P-NRS, S-NRS and DLQI) scores at baseline and after 16 weeks of treatment.
RESULTS: Two hundred and seventy-six patients were enrolled in the study. They represented 11.37% of all patients with severe AD. Flexural eczema was the most frequent clinical phenotype, followed by prurigo nodularis. The coexistence of more than one phenotype was found in 63/276 (22.82%) subjects. Data on the 16-week treatment with dupilumab were available for 253 (91.67%) patients. Efficacy of dupilumab was demonstrated by a significant reduction of all the scores. No statistically significant difference regarding efficacy was found in elderly patients when compared to the group of our AD patients aged 18-64 years, treated with dupilumab over the same period. Furthermore, only 18 (6.52%) patients discontinued the drug due to inefficacy. Sixty-one (22.51%) patients reported adverse events, conjunctivitis and flushing being the most frequent. One (0.36%) patient only discontinued dupilumab due to an adverse event.
CONCLUSIONS: Therapy with dupilumab led to a significant improvement of AD over a 16-week treatment period, with a good safety profile. Therefore, dupilumab could be considered as an efficacious and safe treatment for AD also in the elderly.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:35 |
|---|---|
| Enthalten in: |
Journal of the European Academy of Dermatology and Venereology : JEADV - 35(2021), 4 vom: 05. Apr., Seite 958-964 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Patruno, C [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
420K487FSG |
|---|
| Anmerkungen: |
Date Completed 14.05.2021 Date Revised 14.05.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/jdv.17094 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM318977087 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM318977087 | ||
| 003 | DE-627 | ||
| 005 | 20231225170502.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/jdv.17094 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1063.xml |
| 035 | |a (DE-627)NLM318977087 | ||
| 035 | |a (NLM)33332697 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Patruno, C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Dupilumab therapy of atopic dermatitis of the elderly |b a multicentre, real-life study |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.05.2021 | ||
| 500 | |a Date Revised 14.05.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 European Academy of Dermatology and Venereology. | ||
| 520 | |a BACKGROUND: Treatment of moderate-to-severe atopic dermatitis (AD) in the elderly may be challenging, due to side-effects of traditional anti-inflammatory drugs and to comorbidities often found in this age group. Furthermore, efficacy and safety of innovative drugs such as dupilumab are not yet well known | ||
| 520 | |a OBJECTIVES: A multicentre retrospective, observational, real-life study on the efficacy and safety of dupilumab was conducted in a group of patients aged ≥65 years and affected by severe AD. Their main clinical features were also examined | ||
| 520 | |a METHODS: Data of elderly patients with severe (EASI ≥24) AD treated with dupilumab at label dosage for 16 weeks were retrospectively collected. Treatment outcome was assessed by comparing objective (EASI) and subjective (P-NRS, S-NRS and DLQI) scores at baseline and after 16 weeks of treatment | ||
| 520 | |a RESULTS: Two hundred and seventy-six patients were enrolled in the study. They represented 11.37% of all patients with severe AD. Flexural eczema was the most frequent clinical phenotype, followed by prurigo nodularis. The coexistence of more than one phenotype was found in 63/276 (22.82%) subjects. Data on the 16-week treatment with dupilumab were available for 253 (91.67%) patients. Efficacy of dupilumab was demonstrated by a significant reduction of all the scores. No statistically significant difference regarding efficacy was found in elderly patients when compared to the group of our AD patients aged 18-64 years, treated with dupilumab over the same period. Furthermore, only 18 (6.52%) patients discontinued the drug due to inefficacy. Sixty-one (22.51%) patients reported adverse events, conjunctivitis and flushing being the most frequent. One (0.36%) patient only discontinued dupilumab due to an adverse event | ||
| 520 | |a CONCLUSIONS: Therapy with dupilumab led to a significant improvement of AD over a 16-week treatment period, with a good safety profile. Therefore, dupilumab could be considered as an efficacious and safe treatment for AD also in the elderly | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a dupilumab |2 NLM | |
| 650 | 7 | |a 420K487FSG |2 NLM | |
| 700 | 1 | |a Napolitano, M |e verfasserin |4 aut | |
| 700 | 1 | |a Argenziano, G |e verfasserin |4 aut | |
| 700 | 1 | |a Peris, K |e verfasserin |4 aut | |
| 700 | 1 | |a Ortoncelli, M |e verfasserin |4 aut | |
| 700 | 1 | |a Girolomoni, G |e verfasserin |4 aut | |
| 700 | 1 | |a Offidani, A |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrucci, S M |e verfasserin |4 aut | |
| 700 | 1 | |a Amoruso, G F |e verfasserin |4 aut | |
| 700 | 1 | |a Rossi, M |e verfasserin |4 aut | |
| 700 | 1 | |a Stingeni, L |e verfasserin |4 aut | |
| 700 | 1 | |a Malara, G |e verfasserin |4 aut | |
| 700 | 1 | |a Grieco, T |e verfasserin |4 aut | |
| 700 | 1 | |a Foti, C |e verfasserin |4 aut | |
| 700 | 1 | |a Gattoni, M |e verfasserin |4 aut | |
| 700 | 1 | |a Loi, C |e verfasserin |4 aut | |
| 700 | 1 | |a Iannone, M |e verfasserin |4 aut | |
| 700 | 1 | |a Talamonti, M |e verfasserin |4 aut | |
| 700 | 1 | |a Stinco, G |e verfasserin |4 aut | |
| 700 | 1 | |a Rongioletti, F |e verfasserin |4 aut | |
| 700 | 1 | |a Pigatto, P D |e verfasserin |4 aut | |
| 700 | 1 | |a Cristaudo, A |e verfasserin |4 aut | |
| 700 | 1 | |a Nettis, E |e verfasserin |4 aut | |
| 700 | 1 | |a Corazza, M |e verfasserin |4 aut | |
| 700 | 1 | |a Guarneri, F |e verfasserin |4 aut | |
| 700 | 1 | |a Amerio, P |e verfasserin |4 aut | |
| 700 | 1 | |a Esposito, M |e verfasserin |4 aut | |
| 700 | 1 | |a Belloni Fortina, A |e verfasserin |4 aut | |
| 700 | 1 | |a Potenza, C |e verfasserin |4 aut | |
| 700 | 1 | |a Fabbrocini, G |e verfasserin |4 aut | |
| 700 | 0 | |a DADE - Dupilumab for Atopic Dermatitis of the Elderly study group |e verfasserin |4 aut | |
| 700 | 1 | |a Angileri, L |e investigator |4 oth | |
| 700 | 1 | |a Bianchelli, T |e investigator |4 oth | |
| 700 | 1 | |a Borghi, A |e investigator |4 oth | |
| 700 | 1 | |a Buligan, C |e investigator |4 oth | |
| 700 | 1 | |a Calabrese, G |e investigator |4 oth | |
| 700 | 1 | |a Calzavara Pinton, P |e investigator |4 oth | |
| 700 | 1 | |a Caroppo, F |e investigator |4 oth | |
| 700 | 1 | |a Chello, C |e investigator |4 oth | |
| 700 | 1 | |a Dal Bello, G |e investigator |4 oth | |
| 700 | 1 | |a Damiani, G |e investigator |4 oth | |
| 700 | 1 | |a Fargnoli, M C |e investigator |4 oth | |
| 700 | 1 | |a Ferrillo, M |e investigator |4 oth | |
| 700 | 1 | |a Galluzzo, M |e investigator |4 oth | |
| 700 | 1 | |a Gori, N |e investigator |4 oth | |
| 700 | 1 | |a Gualdi, G |e investigator |4 oth | |
| 700 | 1 | |a Hansel, K |e investigator |4 oth | |
| 700 | 1 | |a Macchia, L |e investigator |4 oth | |
| 700 | 1 | |a Mariano, M |e investigator |4 oth | |
| 700 | 1 | |a Nisticò, S P |e investigator |4 oth | |
| 700 | 1 | |a Pertusi, G |e investigator |4 oth | |
| 700 | 1 | |a Piras, V |e investigator |4 oth | |
| 700 | 1 | |a Provenzano, E |e investigator |4 oth | |
| 700 | 1 | |a Ravaioli, G M |e investigator |4 oth | |
| 700 | 1 | |a Ribero, S |e investigator |4 oth | |
| 700 | 1 | |a Romanelli, M |e investigator |4 oth | |
| 700 | 1 | |a Romita, P |e investigator |4 oth | |
| 700 | 1 | |a Tolino, E |e investigator |4 oth | |
| 700 | 1 | |a Trifirò, C |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the European Academy of Dermatology and Venereology : JEADV |d 1997 |g 35(2021), 4 vom: 05. Apr., Seite 958-964 |w (DE-627)NLM091705932 |x 1468-3083 |7 nnns |
| 773 | 1 | 8 | |g volume:35 |g year:2021 |g number:4 |g day:05 |g month:04 |g pages:958-964 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/jdv.17094 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 35 |j 2021 |e 4 |b 05 |c 04 |h 958-964 | ||